- Identifying critical challenges in CMC for cell therapies and strategizing solutions for overcoming them
- Exploring how deeper insights into cells, their critical quality attributes, and control mechanisms can enhance safety, efficacy, and manufacturing efficiency
- Discussing strategies for manufacturing autologous, allogeneic, and next-generation autologous therapies
- Outlining a roadmap for developing an innovative, flexible, and modular platform to facilitate true industrialization of cell therapy in the near future
- Examining partnering models that integrate innovation engines with global supply networks to translate concepts into tangible solutions
Thomas Potgieter
Senior Vice President, Cell Therapy Development & Operations
Bristol Myers Squibb
Thomas has been serving as the Senior Vice President of Cell Therapy Development and Operations at BMS since August 2023. Before joining BMS, he held multiple roles with Merck & Co, where he gained experience in basic research, early and late-stage process development, capital project management, site-based technical operations, commercialization, manufacturing science and technology, and supply chain. Before that, Thomas worked for startup, GlycoFi, founded at Dartmouth College, where he conducted post-doctoral research after receiving his PhD in Bioprocess Engineering from the University of Cape Town in South Africa.
